The withdrawal of Biogen Idec Inc. and Elan Corp.'s natalizumab (Tysabri) multiple sclerosis treatment just weeks after its introduction showed that specialist products aren't immune from serious safety issues. Sales and clinical trials of the drug were suspended with the cooperation of the FDA after two patients in the companies' clinical study of Tysabri in combination with Avonex developed the rare and often fatal demyelinating disorder PML.
Just when you thought it was safe to get back in the water.
The withdrawal of Biogen Idec Inc. and Elan Corp. PLC 's natalizumab (Tysabri) multiple sclerosis treatment showed that...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
